Get started

Aridispharmaceuticals

ARDS receives grant from the Bill & Melinda Gates FoundationARDS Aridis Pharmaceuticals received a grant award from the Bill & Melinda Gates Foundation to evaluate the application of Aridis' inhaled formulation technology to deliver cost-effective monoclonal antibodies (mAbs) against influenza and SARS-CoV2. Aridis Pharmaceuticals is a stock with a mk cap of only 28.249Mil. Before Aridis, Bill & Melinda Gates Foundation Covid-19 Response investments were in giant companies like: Abbott Laboratories, Gavi / Serum, Lilly mAb, SD Biosensor, UNICEF VII and World Health Organization. AstraZeneca PLC ( AZN ) has a stake in Aridis Pharmaceuticals. CEO has co-developed several drug which have been sold to Astra Zeneca, Megabits and MedImmune. Aridis Pharmaceuticals can be a potential buyout for AZN . Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain." Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment! Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated." ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses. It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment. With this investment, i think ARDS is at least an 100Mil mk cap stock. So 4X from here.
ALong
by TopgOptions
5
ARDS first Investor call of 2022. Phase 3 news ???Aridis Pharmaceuticals announced first Investor call of 2022 for today, after the closing bell. Exiting pipeline with 2 phase 3 drugs and their monoclonal antibody cocktail. AstraZeneca PLC (AZN) has a stake in this company. CEO has co-developed several drug which have been sold to Astra Zeneca, Megabits and MedImmune. Aridis Pharmaceuticals can be a potential buyout for AZN. Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain." Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment! Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated." ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses. It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment. Market Cap of only 22.48Mil 52 Week Range 1.13 - 8.4
ALong
by TopgOptions
2
ARDS 1250% upside potential according to H.C. Wainwright !!!Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain." Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment! Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated." ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses. It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment. Market Cap of only 21.22Mil 52 Week Range 1.49 - 8.47 You can buy the all time low now!
ALong
by TopgOptions
ARDS Covid-19 Antibody Cocktail | Massive Bullish DivergenceThe chart speaks for itself: ARDS is in a massive bullish divergence at all time low levels from which can explode anytime soon! Recently, analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS , told investors that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain." Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated." ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses. It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment. Market Cap 27.124Mil 52 Week Range 1.89 - 8.47 I think this might be our 10X stock for 2022.
ALong
by TopgOptions
ARDS Covid-19 First-in-Class Antibody | +818% Analyst Rating ! Analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS, told investors Wednesday that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain." Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated." ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses. It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment. Market Cap of only 32.605Mil 52 Week Range 1.89 - 8.47 I think this might be our 10X stock for 2022. Happy New Year!
ALong
by TopgOptions
2